NMRA - NOTRELOAD AI

NMRA/ 01/05/2026 · 9:16 AM

Neumora Shows Promise with New Alzheimer's Agitation Treatment

Neumora Therapeutics (NMRA) announces positive Phase 1b results for NMRA-511, a new drug candidate showing clinically meaningful improvements in Alzheimer's disease agitation symptoms with favorable safety profile.

NMRA/ 12/01/2025 · 11:05 AM

RBC Capital Upgrades Neumora Therapeutics to Outperform

RBC Capital raises Neumora Therapeutics to Outperform, citing new growth opportunities beyond neurology and promising early data in multiple markets.

Featured/ NMRA/ 10/27/2025 · 8:43 AM

Guggenheim Upgrades Neumora Therapeutics on Breakthrough Obesity Drug Results

Guggenheim upgrades Neumora to Buy with $14 target after impressive preclinical obesity data shows up to 26% weight loss with NLRP3 inhibitor NMRA-215.

#NMRA↓

Neumora Shows Promise with New Alzheimer's Agitation Treatment

RBC Capital Upgrades Neumora Therapeutics to Outperform

Guggenheim Upgrades Neumora Therapeutics on Breakthrough Obesity Drug Results